Because recent reports demonstrated the increased risks of pancreatitis and pancreatic cancer in patients chronically treated with GLP-1 analogs and DPP4 inhibitors (Gier et al., 2012), it would be necessary to monitor the potential toxicity of long-term pancreatic GLP-1 overexpression on pancreatitis and pancreatic cancers in mice. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.